FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?-Reference-Cited by-同舟云学术

FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?

Published:2023-01-31 Issue:3 Volume:24 Page:2685
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Psilopatis Iason¹^ORCID,Damaskos Christos²³^ORCID,Garmpi Anna⁴,Sarantis Panagiotis⁵^ORCID,Koustas Evangelos⁵,Antoniou Efstathios A.³⁶,Dimitroulis Dimitrios⁶,Kouraklis Gregory⁶,Karamouzis Michail V.⁵^ORCID,Vrettou Kleio⁷,Marinos Georgios⁸,Kontzoglou Konstantinos³⁶,Garmpis Nikolaos³⁶^ORCID

Affiliation:

1. Department of Gynecology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

2. Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece

3. N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

4. First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

5. Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

6. Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

7. Department of Cytopathology, Sismanogleio General Hospital, 15126 Athens, Greece

8. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

Abstract

Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first- or second-line monoclonal antibodies (mAbs) for unresectable HCC. The present review examines the current state of knowledge, and provides a useful update on the safety and efficacy of these therapeutic agents, thus attempting to define the suitability of each mAb for different patient subgroups.

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

https://www.mdpi.com/1422-0067/24/3/2685/pdf

Reference115 articles.

1. (2022). Key Statistics about Liver Cancer.

2. Damaskos, C., Garmpis, N., Dimitroulis, D., Garmpi, A., Psilopatis, I., Sarantis, P., Koustas, E., Kanavidis, P., Prevezanos, D., and Kouraklis, G. (2022). Targeted therapies for hepatocellular carcinoma treatment: A new era ahead—A systematic review. Int. J. Mol. Sci., 23.

3. (2019). Signs and Symptoms of Liver Cancer, American Cancer Society.

4. (2019). Can Liver Cancer Be Found Early?, American Cancer Society.

5. (2021). Treatment of Liver Cancer, American Cancer Society.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma;Frontiers in Immunology;2024-08-09

2. ULK1 Mediated Autophagy-Promoting Effects of Rutin-Loaded Chitosan Nanoparticles Contribute to the Activation of NF-κB Signaling Besides Inhibiting EMT in Hep3B Hepatoma Cells;International Journal of Nanomedicine;2024-05

3. Synchronous Double Primary Tumors of Liver (Small Cell Neuroendocrine Carcinoma and Hepatocellular carcinoma): A Case Report;Hepatic Medicine: Evidence and Research;2024-04

4. Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies;Pathology - Research and Practice;2024-04

5. Downstaging Techniques for Hepatocellular Carcinoma in Candidates Awaiting Liver Transplantation;Surgical Clinics of North America;2024-02